Initial sequencing and analysis of the human genome.International Human Genome Sequencing ConsortiumLander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., Devon K., Dewar K., Doyle M.[...], Szustakowki J.View abstractCited forNUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]CategorySequencesSourceUniProtKB unreviewed (TrEMBL)PubMedEurope PMCNature 409:860-921 (2001)Cited in99+
The DNA sequence and comparative analysis of human chromosome 20.Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., Jones M., Stavrides G., Almeida J.P., Babbage A.K.[...], Rogers J.View abstractCited forNUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]CategorySequencesSourceUniProtKB unreviewed (TrEMBL)PubMedEurope PMCNature 414:865-871 (2001)Cited in99+99+
The sequence of the human genome.Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., Smith H.O., Yandell M., Evans C.A.[...], Zhu X.View abstractCited forNUCLEOTIDE SEQUENCECategorySequencesSourceUniProtKB unreviewed (TrEMBL)PubMedEurope PMCScience 291:1304-1351 (2001)Cited in499+
MOZ Is fused to a novel Polycomb group gene in a therapy-related myelodysplastic syndrome with t(2;8)(p23;p11.2).Hosoda F., Kitabayashi I., Kakazu N., Fukushima M., Aikawa Y., Abe T., Hibi S., Yagi T., Ohki M.Cited forNUCLEOTIDE SEQUENCECategorySequencesSourceUniProtKB unreviewed (TrEMBL)Submission Submitted to EMBL/GenBank/DDBJ databases (APR-2002)Cited in1
Finishing the euchromatic sequence of the human genome.International Human Genome Sequencing ConsortiumView abstractCited forNUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]CategorySequencesSourceUniProtKB unreviewed (TrEMBL)PubMedEurope PMCNature 431:931-945 (2004)Cited in99+
No title available.Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., Lippert R., Walenz B., Shatkay H.[...], Venter J.C.Cited forNUCLEOTIDE SEQUENCECategorySequencesSourceUniProtKB unreviewed (TrEMBL)Submission Submitted to EMBL/GenBank/DDBJ databases (SEP-2005)Cited in99+99+
A quantitative atlas of mitotic phosphorylation.Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P.View abstractCited forIDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]CategorySequencesSourceUniProtKB unreviewed (TrEMBL)PubMedEurope PMCProc. Natl. Acad. Sci. U.S.A. 105:10762-10767 (2008)Cited in99+99+
Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., Rodionov V., Han D.K.View abstractCited forIDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]CategorySequencesSourceUniProtKB unreviewed (TrEMBL)PubMedEurope PMCSci. Signal. 2:RA46-RA46 (2009)Cited in99+99+
Toward a comprehensive characterization of a human cancer cell phosphoproteome.Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., Mohammed S.View abstractCited forIDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]CategorySequencesSourceUniProtKB unreviewed (TrEMBL)PubMedEurope PMCJ. Proteome Res. 12:260-271 (2013)Cited in99+99+
No title available.EnsemblCited forIDENTIFICATIONSourceUniProtKB unreviewed (TrEMBL)Submission Submitted to UniProtKB (AUG-2024)Cited in99+
[Relationship between DTA Mutations and Thromboembolism in Patients with Myeloproliferative Neoplasms].Wang M., Zhao H.Y., Li D.Q., Chen P.View abstractSourceGeneRif: 171023PubMedEurope PMCZhongguo Shi Yan Xue Ye Xue Za Zhi 32:819-824 (2024)Mapped to14
Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119.Kohnke T., Nuno K.A., Alder C.C., Gars E.J., Phan P., Fan A.C., Majeti R.View abstractAnnotationHuman ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119.CategoryFunctionSourceGeneRif: 171023PubMedEurope PMCBlood Cancer Discov 5:202-223 (2024)Mapped to5
Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms.Collins T.B., Laranjeira A.B.A., Kong T., Fulbright M.C., Fisher D.A.C., Sturgeon C.M., Batista L.F.Z., Oh S.T.View abstractAnnotationAltered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms.CategoryFunctionSourceGeneRif: 171023PubMedEurope PMCExp Hematol 132:104178-104178 (2024)Mapped to12
Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study.Ahn H.J., An H.Y., Ryu G., Lim J., Sun C., Song H., Choi S.Y., Lee H., Maurer T.[...], Choi E.K.View abstractAnnotationClonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study.CategorySequencesSourceGeneRif: 171023PubMedEurope PMCEur Heart J 45:778-790 (2024)Mapped to14
ASXL1 mutation is a novel risk factor for bleeding in Philadelphia- negative myeloproliferative neoplasms.Awada H., Bhatta M., Yu H., Ji W., Hou S., Cronin T., Ba Aqeel S., Roy A.M., Faisal M.S.[...], Elshoury A.AnnotationASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms.SourceGeneRif: 171023PubMedEurope PMCLeukemia 38:210-214 (2024)Mapped to5
Targeting lysine demethylase 6B ameliorates ASXL1 truncation-mediated myeloid malignancies in preclinical models.Ge G., Zhang P., Sui P., Chen S., Yang H., Guo Y., Rubalcava I.P., Noor A., Delma C.R.[...], Yang F.C.View abstractAnnotationTargeting lysine demethylase 6B ameliorates ASXL1 truncation-mediated myeloid malignancies in preclinical models.CategoryFunctionSourceGeneRif: 171023PubMedEurope PMCJ Clin Invest 134:e163964-e163964 (2024)Mapped to9
Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1.Thomas J.F., Valencia-Sanchez M.I., Tamburri S., Gloor S.L., Rustichelli S., Godinez-Lopez V., De Ioannes P., Lee R., Abini-Agbomson S.[...], Armache K.J.View abstractAnnotationStructural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1.CategoryPTM / ProcessingSourceGeneRif: 171023PubMedEurope PMCSci. Adv. 9:eadg9832-eadg9832 (2023)Cited in2Mapped to14
Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.Jain T., Ware A.D., Dalton W.B., Pasca S., Tsai H.L., Gocke C.D., Gondek L.P., Xian R.R., Borowitz M.J., Levis M.J.View abstractAnnotationCo-occurring mutations in ASXL1 SRSF2 and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.CategoryFunctionSourceGeneRif: 171023PubMedEurope PMCLeuk Res 131:107345-107345 (2023)Mapped to15
Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.Feng Y., Liang H., Han M., Luo X., Zhu Y., Liu B.View abstractAnnotationAnalysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.CategoryDisease & VariantsSourceGeneRif: 171023PubMedEurope PMCHematology 28:2220222-2220222 (2023)Mapped to8
Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression.Yan X., Xu Z., Zhang P., Sun Q., Jia Y., Qin T., Qu S., Pan L., Li Z.[...], Xiao Z.AnnotationNon-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression.CategoryFunctionSourceGeneRif: 171023PubMedEurope PMCBlood Cancer J 13:56-56 (2023)Mapped to5
Epigenetic regulation by ASXL1 in myeloid malignancies.Yang F.C., Agosto-Pena J.View abstractAnnotationEpigenetic regulation by ASXL1 in myeloid malignancies.SourceGeneRif: 171023PubMedEurope PMCInt J Hematol 117:791-806 (2023)Mapped to5
Basis of the H2AK119specificity of the Polycomb repressive deubiquitinase.Ge W., Yu C., Li J., Yu Z., Li X., Zhang Y., Liu C.P., Li Y., Tian C.[...], Xu R.M.View abstractAnnotationBasis of the H2AK119 specificity of the Polycomb repressive deubiquitinase.CategoriesFamily & Domains, InteractionSourceGeneRif: 171023PubMedEurope PMCNature 616:176-182 (2023)Cited in2Mapped to15
Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis.Zhang A., Wang S., Ren Q., Wang Y., Jiang Z.View abstractAnnotationPrognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis.CategoryFunctionSourceGeneRif: 171023PubMedEurope PMCAsia Pac J Clin Oncol 19:e183-e194 (2023)Mapped to5
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia.Bidikian A., Kantarjian H., Jabbour E., Short N.J., Patel K., Ravandi F., Sasaki K., Issa G.C.View abstractAnnotationPrognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia.CategoriesSequences, Disease & VariantsSourceGeneRif: 171023PubMedEurope PMCBlood Cancer J 12:144-144 (2022)Mapped to5
Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta- analysis.Lipilkin P.V., Kulaeva E.D., Mashkina E.V.View abstractAnnotationPrognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis.CategoriesSequences, Disease & VariantsSourceGeneRif: 171023PubMedEurope PMCLeuk Res 120:106910-106910 (2022)Mapped to5